Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DATOPOTAMAB DERUXTECAN-DLNK vs DEFIBROTIDE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

DATOPOTAMAB DERUXTECAN-DLNK vs DEFIBROTIDE: Safety Overview

Metric DATOPOTAMAB DERUXTECAN-DLNK DEFIBROTIDE
Total FAERS Reports 165 3,740
Deaths Reported 36 1,804
Death Rate 21.8% 48.2%
Hospitalizations 33 832
Average Patient Age 61.4 yrs 36.3 yrs
% Female Patients 89.2% 38.7%
FDA Approval Date N/A Mar 30, 2016
Manufacturer N/A Jazz Pharmaceuticals, Inc.
Route N/A INTRAVENOUS
Marketing Status Prescription Prescription